Fate Therapeutics, Inc.
NASDAQ:FATEBiotechnology
-$0.00 today
- Market cap
- $122.39M
- Beta
- 2.52
- P/E (TTM)
- -1.8
- EPS (TTM)
- -$1.08
Volume 1.87M
Average 2.92M
FATE Net Income
Bottom-line profit, the starting point for calculating cash from operations.
Fate Therapeutics, Inc.NASDAQ: FATE
Net Income · Q1 FY2026 · quarter ended Mar 2026
Net income declines year over year
Q1 FY2026 net income of $31.21M (cash outflow) fell 17.0% year over year, ahead of the -26.1% change in trailing-twelve-month net income. Sequentially, it fell 3.6% from the prior quarter. Over 3 fiscal years it compounded at -21.5% a year.
Context
- Net income amounted to 2051.1% of revenue in FY2025, up 684.6 pp from a year earlier.
- Net income grew in size in 1 of the last 3 fiscal years.
- FY2025 was the smallest annual figure in the 4 fiscal years shown.
What to watch
Whether net income reaches the consensus estimate from 6 analysts of -$118.9M (-12.8%) for the fiscal year ending Dec 2026, a step up from the -26.8% reported in FY2025.
Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$31.21M-3.6% QoQ
- Last fiscal yearDec 2025
- -$136.32M-26.8% YoY
- LTMMar 2026
- -$129.91M-26.1% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -17.0% | -3.0% | +14.0 pp |
| 1 year | -26.8% | -12.8% | +14.0 pp |
| 3-year CAGR | -21.5% | +6.8% | +28.3 pp |
| 5-year CAGR | -7.1% | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the cash flow
- Latest · FY2025
- (136.32M) USD
- Year-over-year change
- +26.8%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (136.32M) | +26.8% |
| FY2024 | 2024-12-31 | (186.26M) | -15.7% |
| FY2023 | 2023-12-31 | (160.93M) | +42.9% |
| FY2022 | 2022-12-31 | (281.72M) | -32.8% |
| FY2021 | 2021-12-31 | (212.15M) | — |
Net Income vs competitors
How FATE compares with its peers on the latest reported figures
- Peers report in different currencies, so net income is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -26.1% is the 9th highest of 10, against a peer median of -2.6%.
- Net income amounts to 2056.8% of revenue for FATE, versus a peer median of 573.1%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $883.08M USD | +644.6% | +96.2% | — | |
| LTM Mar 2026 | $129.91M USD | -26.1% | -21.5% | 2056.8% | |
| LTM Mar 2026 | $125.39M USD | +1.6% | +2.3% | 680.8% | |
| LTM Mar 2026 | $113.28M USD | -2.6% | +41.5% | — | |
| LTM Mar 2026 | $99.93M USD | -10.2% | -2.9% | — | |
| LTM Mar 2026 | $84.93M USD | -12.0% | -32.8% | — | |
| LTM Mar 2026 | $84.53M USD | +68.1% | +22.9% | — | |
| LTM Mar 2026 | $77.8M USD | -39.1% | -4.8% | 465.3% | |
| LTM Mar 2026 | $77.22M USD | -24.4% | +9.1% | — | |
| LTM Mar 2026 | CHF 64.16M CHF | +7.8% | — | — | |
| Peer median (excluding FATE) | — | -2.6% | +5.7% | 573.1% | |
Competitors are the stored peer set for FATE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (212.15M) | (281.72M) | (160.93M) | (186.26M) | (136.32M) |
| Depreciation & Amortization | 5.85M | 13.76M | 18.28M | 18.96M | 9.3M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 54.36M | 78.73M | 43.46M | 41.5M | 24.92M |
| Change in Working Capital | 2.1M | (34.71M) | 19.18M | (1.96M) | (3.74M) |
| Accounts Receivables | (3.16M) | (29.8M) | 36.65M | (1.11M) | 2.62M |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 0 | 14.25M | (28.94M) | (1.66M) | (9.03M) |
| Other Working Capital | 5.26M | (19.16M) | 11.47M | 816K | 2.66M |
| Other Non-Cash Items | (13.03M) | (24.27M) | (52.26M) | 4.89M | (247K) |
| Operating Cash Flow | (162.87M) | (248.21M) | (132.26M) | (122.87M) | (106.08M) |
| Capital Expenditures | (50.7M) | (35.57M) | (6.15M) | (730K) | (5.95M) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 362K |
| Purchases of Investments | (968.16M) | (404.8M) | (358.81M) | (317.75M) | (195.14M) |
| Sales of Investments | 694.84M | 607.11M | 477.63M | 330.7M | 311.9M |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (324.02M) | 166.75M | 112.67M | 12.22M | 111.17M |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 411.74M | 9.21M | 85K | 94.82M | 0 |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 41.39M | 0 | 0 | 5.07M | 5.49M |
| Financing Cash Flow | 453.13M | 9.21M | 85K | 99.89M | 5.49M |
| Effect of Forex Changes | 0 | 0 | 50K | 4.95M | 0 |
| Net Change in Cash | (33.76M) | (72.25M) | (19.46M) | (5.81M) | 10.57M |
| Free Cash Flow | (213.57M) | (283.77M) | (138.42M) | (123.6M) | (112.04M) |
Fate Therapeutics, Inc.
NASDAQ:FATE
Intrinsic Alpha fair value
Locked
Current Price
$1.05
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.